drugset / Trial / NCT00214630

LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes

NCT00214630

Phase 3 Completed 825 enrolled AstraZeneca
RandomizedSingle-groupOpen-labelTreatment

Summary

Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes

Timeline

Start
2003-12
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 80 mg
Subject Rosuvastatin Small molecule 20 mg
Subject Rosuvastatin Small molecule 40 mg